Liminal BioSciences — Investor Presentation (January 2023)
21 slides from Liminal BioSciences's investor presentation, Jan 6, 2023
Slide 1: Corporate Presentation
Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL January 2023 Exhibit 99.1
Slide 2: Safe Harbour
Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, the Company’s ability to regain compliance with th
Slide 3: Liminal Introduction
Aiming to develop proprietary, novel, best/first in class novel small molecule therapeutics for inflammatory, metabolic and fibrotic diseases Liminal Introduction Pipeline is positioned to deliver multiple value catalysts in 2023/2024 Intellectual property (IP) all under the control of Liminal BioSc
Slide 4: Management Team
LMNL is led by a strong, experienced team with proven track records in the discovery, development, and approval of biopharmaceuticals, all driven to make a difference. Management Team Bruce Pritchard Chief Executive Officer Executive Finance Positions: Prometic Life Sciences Inc., CV Therapeutics In
Slide 5: Value Creation Strategy Aimed at Best or First in Class Drug Discovery & Development
At Liminal, we are focused on elucidating compelling biological mechanisms and plan to advance a pipeline of small molecule therapeutics with best/first-in-class potential across a range of clinical indications with significant commercial prospects. Compelling Biological Mechanisms Data-Driven. Dedi
Slide 6: Our Driving Force
Drive pipeline to quickly advance multiple assets into the clinic Seek opportunities to drive liquidity and trading in the stock Develop a pipeline of candidates for commercially viable target indications Our Driving Force Our aim is to rebuild value through four key drivers. Extend cash as non-dilu
Slide 7: Our Pipeline
Our Pipeline © 2023 Liminal BioSciences Inc.
Slide 8: Building a Pipeline of Antagonists
Both our GPR84 antagonist and OXER1 antagonist are considered seven transmembrane G protein-coupled receptors (7TM GPCR’s), the receptor protein passes through the cell membrane seven times. Around 35% of all approved drugs target GPCR’s, and GPCR’s are considered very “druggable”1 An agonist is a d
Slide 9: GPR84 Antagonist with Numerous Potential Clinical Applications
Target Receptor for orphan GPC receptor GPR84 Rationale Blocks a proinflammatory modulator on immune cells, including macrophages, once inflammation is established1 Liminal IP Novel IP Potential Clinical Applications Many pro-inflammatory conditions2 such as: Inflammatory bowel disease (Crohn’s Dise
Slide 10: GPR84: Role in Inflammation and Fibrosis
GPR84: Role in Inflammation and Fibrosis ROS = Reactive oxygen species = GPR84 = agonist Neutrophil Monocyte/Macrophage Pro-inflammatory/ Pro-fibrotic Activity GPR84 Agonists Pro-inflammatory cytokines Oxidative burst / ROS Chemotaxis Inflammatory conditions increase GPR84 expression
Slide 11: Next Steps for GPR84 Antagonist Program
Next Steps for GPR84 Antagonist Program Based on the data from development work so far, we have nominated our lead preclinical drug candidate for our GRPR84 Antagonist program, LMNL6511. LMNL6511 Properties Low molecular weight Highly selective: no significant off-target liabilities noted in the com
Slide 12: OXER1 Antagonist
OXER1 Antagonist 12
Slide 13: OXER1 Antagonist with Numerous Clinical Applications
Target Receptor for inflammatory mediator 5-oxo-ETE Rationale Blocks potent proinflammatory mediator on eosinophils1 Liminal IP Novel IP Potential Clinical Applications Numerous acute and chronic allergic, inflammatory, and proliferative disease mediated by eosinophils2, such as: Severe eosinophilic
Slide 14: OXER1: Role in Tissue Repair and Inflammation
OXER1: Role in Tissue Repair and Inflammation 1. Gail et al, 2009 What is the OXER1 Receptor? OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells. OXER1 is highly selective for 5-oxo-ETE, one of the most powerful chemo-attractants and activators of eosinophils. Why are eosinophi
Slide 15: OXER1 Potential To Treat Eosinophilic-Driven Disease
OXER1 Potential To Treat Eosinophilic-Driven Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinoph
Slide 16: Development Rationale & Opportunities in Eosinophil-related Diseases
Development Rationale & Opportunities in Eosinophil-related Diseases There are many drug development approaches to limit eosinophil-related tissue damage Eosinophil-targeting biology proven with existing, approved, monoclonal antibody drugs Reducing eosinophil levels shown to improve outcomes in sev
Slide 17: Potential Expansion of R&D Portfolio
Opportunity to expand pipeline to study additional diversified candidates from the in-house discovery engine (over 3,000 compounds already generated). In-House Drug Discovery Engine Potential for in-house compounds to be augmented by in-licensed compounds. In-Licensed Compounds Potential to enter in
Slide 18: Business Summary
Business Summary © 2023 Liminal BioSciences Inc. 18
Slide 19: Data Driven Execution and Delivery: Expected Program Milestones
Data Driven Execution and Delivery Expected Program Milestones GPR84 Antagonist Program 2023: Pre-clinical candidate selection and guidance on potential target disease areas 2023: Commence IND/CTA enabling studies for regulatory approval of clinical trial 2023: Regulatory submission for Phase 1 clin
Slide 20: Data Driven Execution and Delivery: Potential Business Opportunities
Data Driven Execution and Delivery Potential Business Opportunities Drug Discovery Platform 2023: Opportunity to expand pipeline to study additional candidates with novel targets and novel pathways from in-house discovery engine, in-licenced compounds, or strategic partnering or out-licensing opport
Slide 21: Executive Summary
All figures presented in this section are in Canadian dollars unless otherwise specified. Executive Summary Cash as of December 31, 2022 just over $37M Potential development opportunities from in-house drug discovery platform Ongoing opportunity to monetise non-core assets Access to NASDAQ Market: L
Liminal BioSciences — Investor Presentation (January 2023) on 6ix